Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides

The Prostate
B A TjoaG P Murphy

Abstract

A phase I trial involving patients with advanced prostate cancer was conducted to assess the safe administration of dendritic cells (DC) and HLA-A0201-specific prostate-specific membrane antigen (PSMA) peptides (PSM-P1 or -P2). Thirty-three of the phase I participants were subsequently enrolled in a phase II trial, which involved six infusions of DC pulsed with PSM-P1 and -P2 peptides. Clinical monitoring was conducted up to 770 days from the start of the phase I study. Data collected included: complete blood count, bone and total alkaline phosphatase, prostate markers, physical examination, performance status, bone scan, ProstaScint scan, and chest X-ray, as well as assays to monitor cellular immune responses. Nine partial responders were identified in the phase II study based on National Prostate Cancer Project (NPCP) criteria, plus 50% reduction of prostate-specific antigen. Four of the partial responders were also responders in the phase I study, with an average response duration of 225 days. Their combined average total response period was over 370 days. Five other responders were nonresponders in the phase I study. Their average partial response period was 196 days. The responses observed in the phase I and II clinical tr...Continue Reading

Citations

Mar 22, 2002·The Lancet Oncology·M JeffordI D Davis
Mar 17, 1999·Proceedings of the National Academy of Sciences of the United States of America·P S NelsonK Wang
Aug 4, 1999·Proceedings of the National Academy of Sciences of the United States of America·G HartmannA M Krieg
Jun 30, 2009·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Duane A Mitchell, John H Sampson
Nov 19, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David M LubaroffRichard D Williams
Nov 16, 2010·Clinical & Developmental Immunology·Hanka JähnischMarc Schmitz
Jun 3, 2000·Annual Review of Immunology·L Fong, E G Engleman
Feb 26, 2016·International Immunopharmacology·Keqiang ChenShaobo Su
May 22, 2007·International Journal of Cancer. Journal International Du Cancer·Anna-Katharina Thomas-KaskelHendrik Veelken
May 27, 2006·Experimental Hematology·Anja MoldenhauerAbdulgabar Salama
Aug 2, 2007·Expert Opinion on Biological Therapy·Massimo Trucco, Nick Giannoukakis
Jul 14, 2009·Expert Opinion on Biological Therapy·Lorenzo PillaG Parmiani
Apr 13, 2006·Expert Review of Vaccines·Gentao LiuJohn S Yu
May 11, 2010·Expert Review of Vaccines·Kevin S CliveGeorge E Peoples
Jul 14, 2010·Expert Review of Vaccines·Sheeba Alam, Douglas G McNeel
Aug 24, 2012·Expert Review of Vaccines·David M Lubaroff
Jan 13, 2005·The Journal of Veterinary Medical Science·Makoto BonkobaraKiyoshi Ariizumi
Jan 5, 2000·Seminars in Surgical Oncology·B A Tjoa, G P Murphy
Jan 5, 2000·Seminars in Surgical Oncology·L J Denis, K Griffiths
Jul 1, 1999·The Prostate·B A TjoaG P Murphy
May 27, 1999·The Prostate·S J SimmonsG P Murphy
Jun 14, 2013·PloS One·Stephanie WallnerDominik Wolf
Oct 13, 2006·Cancer Immunology, Immunotherapy : CII·Andrea MarrariLicia Rivoltini
Aug 11, 2000·Journal of Gastroenterology and Hepatology·W ChenR S Stubbs
Jun 19, 2001·Biological Chemistry·N MeidenbauerA Mackensen
Dec 12, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·L FongE G Engleman
Mar 7, 2002·Cancer Practice·G PirtskhalaishviliJ B Nelson

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.